The Safety, Tolerability, and Efficacy of KD01 in Gynecologic Malignancies
NCT06552598
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
97
Enrollment
OTHER
Sponsor class
Conditions
Cervical Cancer
Gynecologic Malignancies
Endometrial Cancer
Interventions
DRUG:
KD01(the recombinant oncolytic adenovirus)
Sponsor
Tongji Hospital